Newstral
Article
Bbarrons.com on 2019-08-14 15:05
Myriad Genetics Craters on Weak Earnings, FDA Scrutiny
Related news
- BMyriad Genetics Sinks After Weak Earnings and a Guidance Cutbarrons.com
- MMyriad Genetics stock plummets 39% after lower-than-expected earnings, FDA questionsmarketwatch.com
- BMyriad Genetics Drops as Enthusiasm Wanesbarrons.com
- BMyriad Genetics Runs Into Trouble With the F.D.A.barrons.com
- BMyriad Genetics Stock Is Jumping. Earnings Were Great.barrons.com
- BMyriad Genetics Stock’s Wild Ride Will Continue, Analyst Saysbarrons.com
- BNio Stock Is Soaring, Myriad Genetics Jumps, as the Dow Holds Its Groundbarrons.com
- BMyriad Genetics Tumbles After Wall Street Journal Highlights Risks of Genetic Testingbarrons.com
- MMyriad Genetics stock plunges to lead premarket losers after earnings miss by wide marginmarketwatch.com
- MAMD’s stock craters more than 20% after hours on weak graphics salesmarketwatch.com
- Spotify Stock Craters to All-Time Low on Weak Paid Subscriber Growthvariety.com
- MMyriad Genetics announces $50 million accelerated share buybackmarketwatch.com
- Myriad Genetics Looks Like A Timely Buy For 2015Forbes
- Homeopathic medicine under FDA scrutinyCNN
- Theranos’ Only FDA Approved Test Is Also Under Scrutiny After Ex-Employee ComplaintTechCrunch
- Seattle Genetics drug wins FDA approval, could boost biotech's revenuebizjournals.com
- FDA to allow limited 23andMe home genetics testKnoxville News Sentinel
- FDA grants approval for Astellas, Seattle Genetics' bladder cancer drugThe Jerusalem Post (JPost.com)
- FDA steps up antibody test scrutinyArkansas Online